Your browser doesn't support javascript.
loading
The prevalence of SARS-CoV-2 infection and other public health outcomes during the BA.2/BA.2.12.1 surge, New York City, April-May 2022.
Qasmieh, Saba A; Robertson, McKaylee M; Teasdale, Chloe A; Kulkarni, Sarah G; Jones, Heidi E; Larsen, David A; Dennehy, John J; McNairy, Margaret; Borrell, Luisa N; Nash, Denis.
Affiliation
  • Qasmieh SA; Institute for Implementation Science in Population Health (ISPH), City University of New York (CUNY), New York, NY, USA.
  • Robertson MM; Department of Epidemiology and Biostatistics, Graduate School of Public Health and Health Policy, City University of New York (CUNY), New York, NY, USA.
  • Teasdale CA; Institute for Implementation Science in Population Health (ISPH), City University of New York (CUNY), New York, NY, USA.
  • Kulkarni SG; Department of Epidemiology and Biostatistics, Graduate School of Public Health and Health Policy, City University of New York (CUNY), New York, NY, USA.
  • Jones HE; Institute for Implementation Science in Population Health (ISPH), City University of New York (CUNY), New York, NY, USA.
  • Larsen DA; Department of Epidemiology and Biostatistics, Graduate School of Public Health and Health Policy, City University of New York (CUNY), New York, NY, USA.
  • Dennehy JJ; Institute for Implementation Science in Population Health (ISPH), City University of New York (CUNY), New York, NY, USA.
  • McNairy M; Institute for Implementation Science in Population Health (ISPH), City University of New York (CUNY), New York, NY, USA.
  • Borrell LN; Department of Epidemiology and Biostatistics, Graduate School of Public Health and Health Policy, City University of New York (CUNY), New York, NY, USA.
  • Nash D; Department of Public Health, Falk College, Syracuse University, Syracuse, NY, USA.
Commun Med (Lond) ; 3(1): 92, 2023 Jun 30.
Article in En | MEDLINE | ID: mdl-37391483
It is difficult to assess the true prevalence of SARS-CoV-2, the virus that causes COVID-19, due to changes in testing practices and behaviors, including increasing at-home testing and decreasing healthcare provider-based testing. We conducted a population-representative survey in New York City to estimate the prevalence of SARS-CoV-2 during the second Omicron surge in spring 2022. We compared survey-based SARS-CoV-2 prevalence estimates with data on diagnosed cases, hospitalizations, deaths, and SARS-CoV-2 concentration in wastewater. Our survey-based estimates were nearly 30 times higher than official case counts and estimates of immunity among those with active infection were high. Taken together, our results suggest that the magnitude of the second Omicron surge was likely significantly underestimated, and high levels of immunity likely prevented a major surge in hospitalizations/deaths. Our findings might inform future work on COVID-19 surveillance and how to mitigate its spread.
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Prevalence_studies / Risk_factors_studies Language: En Journal: Commun Med (Lond) Year: 2023 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Prevalence_studies / Risk_factors_studies Language: En Journal: Commun Med (Lond) Year: 2023 Document type: Article Affiliation country: Country of publication: